Form 144 INSMED Inc Filed by: Bonstein Sara
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to Form 144 INSMED Inc Filed by: Bonstein Sara
May 30, 2024 4:35 PM EDT
Stifel analyst Stephen D. Willey raised the price target on Insmed (NASDAQ: INSM) to $67.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "We believe topline P3 ASPEN results will establish brensocatib as the first-approved, standardof-care therapy in NCFBE and meaningfully improve investor... More
May 29, 2024 5:37 AM EDT
UBS analyst Trung Huynh raised the price target on Insmed (NASDAQ: INSM) to $58.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "Management believes from now through the regulatory review process, the path is noncontroversial given the strength of data presented... More
May 29, 2024 5:30 AM EDT
Truist Securities analyst Nicole Germino raised the price target on Insmed (NASDAQ: INSM) to $68.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "With greater confidence into brensocatib potential approval following positive ASPEN results today and supported by our KOL call last... More
May 29, 2024 5:25 AM EDT
Wolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $54.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "How to think about stock valuation, even assuming a capital raise? The previous stock in the mid-$20s implied POS... More
May 29, 2024 5:08 AM EDT
BofA Securities analyst Jason Zemansky raised the price target on Insmed (NASDAQ: INSM) to $62.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "This mornings positive readout for novel DPP-1 inhibitor brenso (see report: our initial takes on the data) represents a... More
